Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma

This is a multicenter, open-label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of domatinostat in combination with sirolimus in adolescents and adults with relapsed or refractory sarcoma and osteosarcoma.

Trial Details

NCT ID
NCT07725380
Phase
PHASE1 / PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Domatinostat
  • Sirolimus
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843
  • St Louis, Missouri, United States|38.62727,-90.19789
  • The Bronx, New York, United States|40.84985,-73.86641
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Age ≥12 and ≤40 years.
  • Histologically confirmed relapsed or refractory sarcoma (Phase 1) or osteosarcoma (Phase 2).
  • At least one prior standard systemic therapy regimen.
  • Not candidates for available therapies known to provide survival benefit.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →